Content automation is the practice of using systems to perform repetitive tasks to create content; such as formatting, data retrieval, and document assembly. Content automation in the pharmaceutical industry is often implemented for the following reasons:
Artificial intelligence (AI) used to be something we thought about as a future need or threat. Just a couple of years ago, the impact of AI on our daily lives was indirect. Companies employed AI systems that ran behind a user interface. Even though we have interacted with AI for
Content reuse is the practice of creating one piece of content and then using that piece of content everywhere you need it. A reused piece of content is created, finalized, translated, managed, stored, and retired one, and only one, time.
Vigilante content is all the content created (and often distributed) by people who are not tasked with creating content. It’s the content that someone thinks up and then writes. And then publishes or emails or prints to hand out at a conference. In essence, it is unauthorized content.
We can no longer afford the costs of traditional, document-based content management in the pharmaceutical industry. We need pharma companies to prioritize content reuse and automation rather than manual, error-prone legacy processes.